media – Page 2 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

PHARMPACK

Organiser：Reed Sinopharm Exhibitions Time：May 13 – May 15, 2026 Address：No. 333 Songze Avenue, Xujing Town, Qingpu District, Shanghai Exhibition hall：National Exhibition and Convention Center (Shanghai) Product range: Pharmaceutical glass Bottle caps and stoppers Aluminum foil, aluminum-plastic packaging, and aluminum products Packaging printing Capsules and gelatin Pharmaceutical plastic bottles Plastic trays Pharmaceutical PVC rigid sheets Pharmaceutical polyethylene bags Pharmaceutical composite films Pharmaceutical flexible tubes Packaging drums for bulk pharmaceutical chemicals Desiccants Cleanroom garments and materials Aerosol packaging Packaging materials for injectables Other packaging materials About PHARMPACK： As a significant pharmaceutical packaging event in Asia, renowned for its large scale, comprehensive range of products, and gathering of leading overseas enterprises, the Shanghai International Pharmaceutical Packaging Exhibition adopts the theme of “Smart Packaging, Innovation-Driven.” It introduces a series of themed activities, such as the “Innovative Product Display Zone for Pharmaceutical Packaging and Drug Delivery Systems.” The exhibition attracts outstanding pharmaceutical packaging ...
- Source: drugdu
- 49
- April 9, 2026
With revenue surging 7.6 times, another innovative pharmaceutical company delivers outstanding results.

Recently, Wangshan Wangshui released its first financial report since its listing on the Hong Kong Stock Exchange. In 2025, the company’s annual revenue reached RMB 102 million, a year-on-year increase of 762.9% , and the gross profit margin soared from 29.5% to 79.0%. The explosive growth in revenue was mainly due to the rapid increase in sales volume after the launch of the new ED drug and the revenue from licensing new indications for VV116. However, Wangshan Wangshui’s losses widened further to 360 million yuan in 2025, mainly due to share-based payment expenses and listing-related costs. Excluding these one-off factors, the company’s core business’s ability to generate cash is strengthening . 01 The commercialization of the new ED drug got off to a flying start. In 2025, the biggest highlight of Wangshan Wangshui will be the successful NMPA approval of the Class 1 new drug Onveda (seminafil hydrochloride tablets, R&D ...
- Source: drugdu
- 61
- April 8, 2026
$53.7 billion! Lilly’s new betting direction

When Eli Lilly acquired Centessa Pharmaceuticals for $7.8 billion (approximately RMB 53.7 billion), the market saw not only a high-premium deal, but also a strategic positioning for the future of neuroscience. While pharmaceutical giants are betting heavily on popular areas such as weight loss and oncology, why is Eli Lilly going against the grain and investing heavily in “wake-up” drugs? 01 Acquisition at a 41% premium In mergers and acquisitions in the biopharmaceutical industry, the premium often directly reflects the acquirer’s judgment on the value of the target asset. Eli Lilly’s 40.5% premium and the transaction structure of $6.3 billion down payment + $1.5 billion CVR are by no means blindly following the trend, but are based on a deep recognition of Centessa’s core asset – the OX2R agonist combination. From the transaction structure perspective, Eli Lilly’s payment method reflects both its affirmation of Centessa’s existing assets and its avoidance ...
- Source: drugdu
- 61
- April 8, 2026
[Another Achievement] Hengdao Pharmaceuticals’ Peramivir Sodium Chloride Injection Approved for Marketing

Innovation and progress, perseverance and a commitment to excellence – another achievement! Recently, our company’s Class 4 chemical drug, Peramivir Sodium Chloride Injection, received a Drug Registration Certificate issued by the National Medical Products Administration. This is considered equivalent to passing the consistency evaluation of generic drug quality and efficacy, further authoritative recognition of our R&D capabilities. Details are as follows: Basic information about drugs Generic name of the drug: Peramivir Sodium Chloride Injection English name: Peramivir and Sodium Chloride Injection Dosage form: Injection Specifications: 100ml: Peramivir (calculated as C 15 H 28 N 4 O 4 ) 0.15g and Sodium Chloride 0.9g Registration Category: Class 4 Chemical Drugs Listing Authorization Holder: Nanjing Hengdao Pharmaceutical Technology Co., Ltd. Drug Approval Number: National Drug Approval Number H20263763 Indications: Used for influenza A or B. For the treatment of influenza A and B (peramivir is effective in treating influenza A and B, ...
- Source: drugdu
- 56
- April 8, 2026
Good news! Chang Le Pharmaceutical’s Bumetanide Injection has received approval for its Supplemental Drug Application

Recently, Chang Le Pharmaceutical, a subsidiary of Lianhuan Pharmaceutical, received the “Approval Notice for Supplementary Drug Application” issued by the National Medical Products Administration. Bumetanide injection was successfully approved, marking a new stage in the company’s production and supply capacity and quality management level in the field of diuretics, and injecting strong momentum into the company’s high-quality development. Bumetanide injection is a commonly used, potent diuretic in clinical practice, widely applied in the treatment of edematous diseases, hypertension, prevention of acute renal failure, and hyperkalemia, demonstrating significant clinical value. This approval includes a new 1ml:0.5mg product specification, along with simultaneous changes to the manufacturing process, production volume, and packaging materials and containers. Since the project’s inception, Chang Le Pharmaceutical has assembled a professional R&D and production team, conducting systematic pharmaceutical research over several months. Adhering strictly to national drug development principles, the team has carried out comprehensive and in-depth experimental ...
- Source: drugdu
- 51
- April 8, 2026
New Drug Launch | Gan & Lee Pharmaceuticals’ Sitagliptin Metformin Tablets (II) Approved

Beijing, China, April 7, 2026 – Gan & Lee Pharmaceuticals Inc. (hereinafter referred to as “Gan & Lee Pharmaceuticals”, stock code: 603087.SH) announced that its wholly-owned subsidiary, Gan & Lee Pharmaceuticals Shandong Co., Ltd., recently received a drug registration certificate for sitagliptin metformin tablets (II) issued by the National Medical Products Administration (hereinafter referred to as “NMPA”) (Acceptance No.: CYHS2403373, Certificate No.: 2026S00914, Drug Approval No.: H20263765). Sitagliptin and metformin tablets (II) are a combination oral hypoglycemic agent. Each tablet contains 50 mg of sitagliptin phosphate (calculated as sitagliptin) and 850 mg of metformin hydrochloride. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that stimulates insulin release in a glucose-dependent manner and reduces glucagon levels by increasing the level of active incretin. Metformin inhibits hepatic gluconeogenesis, reduces glucose absorption in the small intestine, and improves peripheral tissue sensitivity to insulin by increasing glucose uptake and utilization. This product, in combination with ...
- Source: drugdu
- 50
- April 8, 2026
$400 Million! AI Unicorn Anthropic Acquires Coefficient Bio

On April 7, according to The Information and Eric Newcomer, AI giant Anthropic is continuing its push into healthcare with the acquisition of Coefficient Bio, a previously little-known AI biotechnology startup, in a $400 million stock deal. The acquisition was confirmed by people familiar with the matter, and Coefficient’s PitchBook page also reflects the $400 million transaction.In early April, Anthropic, the U.S. AI unicorn, announced the completion of a $30 billion Series G funding round, valuing the company at $380 billion—a sharp increase from its $183 billion valuation in the previous Series F round. In less than three years since its founding, it has achieved $14 billion in annualized revenue, with growth of more than 10-fold each year over the past three years. Aris Theologis is CEO and co-founder of Coefficient. He previously served as Chief Business Officer of Evozyne and Vice President of Paragon Biosciences. He also has extensive ...
- Source: drugdu
- 46
- April 8, 2026
【EXPERT Q&A】What are the compliance requirements for labels in the EU medical device CE audit?

Drugdu.com expert’s response: In the EU Medical Device CE Certification review, compliance requirements for labeling are of utmost importance to ensure that products conform to relevant regulations and standards. Below is a detailed summary of these requirements: I. Basic Label Content Requirements Product Identification Information: Labels should include essential information such as the product model, batch number, and expiration date to enable regulatory authorities and consumers to accurately understand the product’s information and performance characteristics. Manufacturer Information: The label should clearly indicate the manufacturer’s name, address, as well as the product model and serial number (if applicable). This information aids in tracing the product’s origin and compliance. CE Mark: Products must bear the CE mark in a prominent location, which is a mandatory indication that the product complies with relevant EU regulations. The CE mark should be clearly visible and resistant to wear. Its color is typically white letters on ...
- Source: drugdu
- 47
- April 8, 2026
SINOPHEX SHANGHAI

Organiser：Reed Sinopharm Exhibitions Time：May 13 – May 15, 2026 Address：No. 333 Songze Avenue, Xujing Town, Qingpu District, Shanghai Exhibition hall：National Exhibition and Convention Center (Shanghai) Product range: API (Active Pharmaceutical Ingredient) equipment Decoction piece equipment Pharmaceutical packaging equipment Formulation equipment Other pharmaceutical manufacturing equipment Laboratory equipment and consumables Electronic supervision systems Pharmaceutical grinding equipment Environmental protection and purification equipment Plastic machinery About SINOPHEX： The Shanghai International Pharmaceutical Equipment Exhibition (SINOPHEX, referred to as the Pharmaceutical Equipment Exhibition) serves as a professional platform for learning, communication, and cooperation within China’s pharmaceutical equipment industry. SINOPHEX consistently focuses on industry hotspots such as green production, continuous-flow production, and intelligent manufacturing, providing information and technological support to help Chinese pharmaceutical raw material and formulation manufacturers achieve the goals outlined in “Made in China 2025.” As the industry advances toward Industry 4.0, the further digitalization of production processes is an inevitable trend and ...
- Source: drugdu
- 54
- April 7, 2026
【EXPERT Q&A】How should the biocompatibility of medical devices be carried out?

Drugdu.com expert’s response: The development of medical device biocompatibility requires adherence to a systematic process, integrating international standards (such as the ISO 10993 series) and domestic regulations (such as the GB/T 16886 series), and implementing it in stages from preliminary preparation to continuous monitoring. The specific steps are as follows: I. Preliminary Preparation and Risk Assessment Clarify Device Information Determine the intended use (e.g., implantation, contact with blood/mucous membranes/skin), duration of contact (short-term, long-term, or permanent), and material composition (main structure, coatings, connecting components, etc.). Example: A cardiac stent requires long-term implantation in blood vessels, necessitating a focus on evaluating tissue compatibility and blood compatibility. A disposable syringe requires attention to skin irritation and cytotoxicity. Identify Potential Risks Analyze the biological reactions that materials may trigger, such as allergies, cytotoxicity, local inflammation, coagulation, or hemolysis. Example: Nickel-containing metal materials may cause allergic reactions; rough-surfaced materials may damage tissue cells. Determine ...
- Source: drugdu
- 57
- April 6, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.